Pharmaron Beijing Co., Ltd.
300759
Rang in Aktien
#2354
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a... Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others. The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development. It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services. In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Aktienkurs
$5.58
Marktkapitalisierung
$8.24B
Veränderung (1 Tag)
-3.77%
Veränderung (1 Jahr)
28.36%
Land
CN
Handel Pharmaron Beijing Co., Ltd. (300759)
Kategorie
Healthcare
Operative Marge für Pharmaron Beijing Co., Ltd. (300759)
Operative Marge zum October 2026 TTM: 13.49%
Laut den neuesten Finanzberichten und dem Aktienkurs von Pharmaron Beijing Co., Ltd. beträgt die aktuelle operative Marge (TTM) 13.49%. Am Ende des Jahres 2024 lag die operative Marge bei 17.14%.
Historie der operativen Marge von Pharmaron Beijing Co., Ltd. von 2014 bis 2026
Operative Marge zum Jahresende
| Jahr | Operative Marge | ändert |
|---|---|---|
| 2026 (TTM) | 13.49% | -1.39% |
| 2025 | 13.68% | -20.19% |
| 2024 | 17.14% | 6.99% |
| 2023 | 16.02% | -2.67% |
| 2022 | 16.46% | -36.00% |
| 2021 | 25.72% | -0.27% |
| 2020 | 25.79% | 53.42% |
| 2019 | 16.81% | 24.52% |
| 2018 | 13.50% | 17.80% |
| 2017 | 11.46% | -1.38% |
| 2016 | 11.62% | 79.88% |
| 2015 | 6.46% | 107.72% |
| 2014 | 3.11% | 0.00% |
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Operative Marge | Differenz der operativen Marge | Land |
|---|---|---|---|
| 38.59% | -97.14% |
US
|
|
| -149.01% | -111.05% |
US
|
|
| 25.57% | -98.10% |
AU
|
|
| 31.23% | -97.68% |
BE
|
|
| 28.81% | -97.86% |
NL
|
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.